EMA (EU)
GUIDANCE FINAL
Draft guideline on user safety of topically administered veterinary medicinal products - Revision 1
Published: 9/18/2026Detected: 9/18/2026
Summary preview
Clarifies how applicants should conduct user risk assessments for topically administered veterinary medicinal products, including hazard identification, dermal absorption estimation, exposure scenarios, and risk…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountsafety
dermatology
#user safety
#topically administered veterinary medicinal products
#dermal absorption
#transferable residues
#wipe tests
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026